TFS Capital’s Lipocine LPCN Stock Holding History

TFS Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10,148	Closed	-$2.04M	–	832
2015 Q3	$2.04M	Buy	+10,148	New	+$2.35M	0.2%	156

Other funds holding LPCN

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

TFS Capital's LPCN Position: Q4 2015 in Review

TFS Capital sold out of Lipocine (LPCN) in Q4 2015, closing a stake of 10,148 shares — an estimated $2.04M sold.

TFS Capital first reported a position in LPCN in Q3 2015 and held it in 1 quarter. The position peaked at $2.04M in Q3 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q4 2015.

TFS Capital reported no remaining Lipocine position as of Q4 2015 after selling out during the quarter.
TFS Capital sold 10,148 Lipocine shares in Q4 2015, an estimated $2.04M.
TFS Capital first reported a position in Lipocine in Q3 2015 and held it in 1 quarter.
TFS Capital's Lipocine position peaked at $2.04M in Q3 2015.
47 funds tracked by Wall St. Rank held Lipocine as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.